PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $932,175 | -69.6% | 33,750 | -74.7% | 0.35% | -63.0% |
Q1 2023 | $3,069,396 | +41.0% | 133,452 | -33.1% | 0.94% | +6.1% |
Q4 2022 | $2,177,000 | +29.4% | 199,500 | 0.0% | 0.88% | +90.7% |
Q3 2022 | $1,682,000 | +37.2% | 199,500 | +28.7% | 0.46% | -8.0% |
Q2 2022 | $1,226,000 | -93.3% | 155,000 | -79.9% | 0.50% | -92.9% |
Q1 2022 | $18,216,000 | +69.7% | 769,250 | +145.0% | 7.12% | +68.3% |
Q4 2021 | $10,736,000 | -30.0% | 313,929 | -8.1% | 4.23% | -15.8% |
Q2 2021 | $15,333,000 | +130.3% | 341,650 | +32.9% | 5.02% | +203.9% |
Q1 2021 | $6,659,000 | +27.4% | 257,086 | -0.8% | 1.65% | -13.0% |
Q4 2020 | $5,227,000 | – | 259,283 | – | 1.90% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |